SW203668 

SW203668 is a benzothiazole compound, shows anti-tumor activity against lung cancer cell lines (IC₅₀=0.022-0.116 μM)

SW203668 (0.1, 0.3, 1, 3, and 10 μM) has 2 benzothiazole enantiomers, while (+)-SW203668 is more potent competitor to bind p37/p30 than (-)-SW203668^[1].
SW203668 (1 nM-10 μM; 2 d) inhibits H2122 cells growth with IC₅₀s of 0.029 μM ((+)-SW203668) and 0.007 μM ((-)-SW203668), respectively^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

SW203668 (25 mg/kg; i.p.; single dose) shows a half-life of 8 h in mouse plasma and (6 mg/kg, 20 mg/kg; i.p.; once daily for 15 d) has low toxicity in CD-1 mice^[1].
SW203668 (20 mg/kg; i.p.; once daily for 14 d) preserves sebocytes and significantly increases the number of sebocytes in mice^[1].
SW203668 (20 mg/kg; i.p.; once daily for 14 d) shows antitumor efficacy in dosing immunodeficient nonobese diabetic severe combined immunodeficiency (NOD-SCID) mice harboring an H2122 cell-derived tumor xenograft^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

389.47

C₂₂H₁₉N₃O₂S

1673556-40-5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Discovery of tumor-specific irreversible inhibitors of stearoyl CoA desaturase

  [2]. Theodoropoulos PC, et al. Discovery of tumor-specific irreversible inhibitors of stearoyl CoA desaturase. Nat Chem Biol. 2016 Apr;12(4):218-25.  [Content Brief]